Sort
10,766 grants matching “checkpoint inhibitor”
Contribution of Myeloid-Derived Suppressor Cells to Neuro-Inflammatory Alterations and Disease Progression in Glioblastoma
$654,737Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R35 · FY2023 · NS
Contribution of Myeloid-Derived Suppressor Cells to Neuro-Inflammatory Alterations and Disease Progression in Glioblastoma
$654,737Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R35 · FY2025 · NS
Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer
$654,681Zheng-Rong Lu · Case Western Reserve University · R01 · FY2025 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$654,596Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2020 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$654,594Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2021 · CA
Population Modeling of Bladder Cancer Detection and Control
$654,490Thomas Trikalinos · Brown University · U01 · FY2022 · CA
Diacylglycerol kinase in airway smooth muscle functions
$654,449Deepak A Deshpande · Thomas Jefferson University · R01 · FY2024 · HL
Resistance mechanisms to autophagy-modulating therapies
$654,428Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2025 · CA
Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink Study
$654,143Allison W. Kurian · Stanford University · R01 · FY2025 · CA
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$654,072Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2022 · HL
Targeting natural killer cells to enhance HIV vaccine responses
$654,012Stephen N. Waggoner · Cincinnati Childrens Hosp Med Ctr · R01 · FY2023 · AI
Metabolic basis of B cell lineage leukemia relapse
$653,813Markus Mãschen · University Of California, San Francisco · R35 · FY2016 · CA
Intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer
$653,786Yanhong Liu · Baylor College Of Medicine · R01 · FY2025 · CA
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer
$653,625Timothy R Donahue · University Of California Los Angeles · R01 · FY2025 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$653,623Rebecca L Aft · Washington University · R01 · FY2025 · CA
Population Modeling of Bladder Cancer Detection and Control
$653,602Thomas Trikalinos · Brown University · U01 · FY2023 · CA
Functions of mutant IDH in cholangiocarcinoma
$653,532Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2025 · CA
Functions of mutant IDH in cholangiocarcinoma
$653,532Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2023 · CA
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer
$653,452Timothy R Donahue · University Of California Los Angeles · R01 · FY2024 · CA
Implications of Changes in Islet Exosomal Cargo in Type 1 Diabetes
$653,342Emily K Sims · Indiana University Indianapolis · R01 · FY2025 · DK
Advancing Neurosymbolic AI for Smart and Trustworthy Healthcare
$653,230Qi Long · University Of Pennsylvania · R01 · FY2025 · EB
Defining immune-evasive mechanical signaling in head and neck cancer
$653,172Xaralabos Varelas · Boston University Medical Campus · R01 · FY2024 · DE
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$653,121Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2025 · CA
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
$653,049Tobias M Hohl · Sloan-Kettering Inst Can Research · R01 · FY2021 · AI
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
$653,049Tobias M Hohl · Sloan-Kettering Inst Can Research · R01 · FY2022 · AI